🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Germany / NCT06741423
Active, not recruiting Observational

Distinguishing Retroperitoneal Fibrosis and Sarcoma from Other Retroperitoneal Diseases Via Radiomics

NCT06741423 · tracked via the Priya Life Science Germany tracker
Phase
Observational
Started
2023-11-01
Last updated
2024-12-19

Condition(s) studied

Retroperitoneal SarcomaRetroperitoneal Fibrosis

Investigational drug(s) / intervention(s)

Radiomics Algortihm

Radiomics Algortihm: A radiomics algorithm designed to distinguish retroperitoneal fibrosis from other retroperitoneal tumors and provide recommendations for clinical treatment decisions.

Study summary

A retrospective study utilizing archived CT scans of patients diagnosed with retroperitoneal fibrosis, sarcoma or other malignancies (i.e. lymphoma, germ cell tumors, metastasis, infections, ganglioneuromas) in order to implement a radiomics algorithm which is able to differentiate between these malignancies.

Eligibility

Sex
ALL
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Patients of any age or gender. * CT scans confirming the presence of a retroperitoneal mass. * Confirmed diagnosis of retroperitoneal fibrosis, sarcoma or other malignancies (i.e. lymphoma, germ cell tumors, metastasis, infections, ganglioneuromas) through pathology reports or clinical follow-up. Exclusion Criteria: * Poor quality CT scans where the region of interest is not clearly visible. * Previous treatments or surgeries that might alter the radiomic features of the tumors.

Primary outcome measure(s)

Trial sites (2)

FacilityCityRegionStatus
Peking University International Hospital Beijing China
Universitätsklinikum Mannheim Mannheim Baden-Wurttemberg

More Heidelberg University trials in Germany

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06741423 on ClinicalTrials.gov ↗ ← All trials in Germany